Email Artikel ini REVIEW: EFEK ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI) DAN ANGIOTENSIN RECEPTOR BLOCKER (ARB) SEBAGAI KARDIOPROTEKTOR TERHADAP CARDIOVASCULAR EVENTS
Abstrak
Sebagai obat kardioprotektif, Angiotensin Converting Enzyme Inhibitor (ACEI) dan Angiotensin Receptor Blocker (ARB) digunakan untuk mencegah penyakit kardiovaskular dan mengkontrol tekanan darah. Meskipun telah banyak penelitian yang mempelajari efek ACEI dan ARB, kesetaraan efektivitas antara ACEI dan ARB masih menjadi perdebatan. ACEI diyakini lebih efektif dibandingkan ARB pada berbagai pasien dengan penyakit kardiovaskular. Artikel ini mengulas mekanisme efek ACEI dan ARB sebagai kardioprotektor, serta perbandingan efek ACEI dan ARB terhadap cardiovascular events. Penelusuran artikel dilakukan melalui google scholar dan NCBI. ACEI bekerja dengan menghambat pembentukan angiotensin II yang mampu menyebabkan disfungsi endotel, thrombosis, inflamasi, vasokonstriksi, remodeling, dan disrupsi plak. ARB memberikan hambatan pada terjadinya ikatan antara angiotensin II, baik yang diproduksi dari jalur ACE maupun non-ACE dengan reseptor angiotensin II subtipe 1 (AT1), sehingga ARB lebih efektif dalam mengendalikan tekanan darah. Namun, ARB tidak mengurangi kadar angiotensin II dalam tubuh. ACEI dan ARB tidak berbeda signifikan dalam pencegahan cardiovascular events. ACEI merupakan pilihan pertama, sedangkan ARB digunakan pada intoleransi ACEI karena ARB dapat ditoleransi lebih baik dan dikaitkan dengan kepatuhan pengobatan yang lebih besar.
Kata Kunci: ACEI, ARB, kardioprotektor, cardiovascular events.Teks Lengkap:
PDFReferensi
Ancion, A., Tridetti, J., Trung, M. L. N., Oury, C., & Lancellotti, P. 2019. A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril. Cardiology and therapy, 8(2), 179-191.
Antman, E.M., Anbe, D.T., Armstrong, P.W., Bates, E.R., Green, L.A., Hand, M, et al. 2004, ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction), J Am Coll Cardiol, 44:E1–E211.
Bangalore, S., Fakheri, R., Toklu, B., Ogedegbe, G., Weintraub, H., dan Messerli, F.H. 2016, Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blocker in Patients Without Heart Failure? Insights From 254,301 Patients from Randomized Trials, Mayo Clinic Proceedings, 91(1):51-60.
Bertrand, M.E. 2004, Provision of cardiovascular protection by ACE inhibitors: a review of recent trials, Curr Med Res Opin, 20: 1559-1569.
Brown, N.J. dan Vaughan, D.E. 1998, Angiotensin-converting enzyme inhibitors, Circulation, 97:1411-1420.
Brunner, H. R. 2001. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. The American journal of cardiology, 87(8), 3-9.
Burnier, M. 2001, Angiotensin II type 1 receptor blockers, Circulation, 103:904-912.
Dickstein, K., Kjekshus, J., OPTIMAAL Steering Committee, & OPTIMAAL Study Group. 2002. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet, 360(9335), 752-760.
Dimou, C., Antza, C., Akrivos, E., Doundoulakis, I., Stabouli, S., Haidich, A.B., et al. 2018, A systematic review and network meta-analysis of the comparative efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension, Journal of human Hypertension.
Dzau, V. J. 2001. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension, 37(4), 1047-1052.
Elgendy, I.Y., Huo, T., Chik, V., Pepine, C.J., dan Bavry, A.A. 2015, Efficacy and safety of angiotensin receptor blocker in older patients: a meta-analysis of randomized trials, Am J Hypertens, 28:576-585.
Elliott, W.J. 2000, Therapeutic trials comparing angiotensisn-converting enzyme inhibitors and angiotensin II receptor blockers, Curr Hypertens Rep, 2:402-411.
Fogari, R., Mugellini, A., Zoppi, A., Corradi, L., Paola, P., Lazzari, P., et al. 2002, Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients, Am J Hypertens, 15:316-320.
Ghiadoni, L., Magagna, A., Versari, D., Kardasz, I., Huang, Y., Taddei, S., et al. 2003, Different effect of antihypertensive drugs on conduit artery endothelial function, Hypertension, 41:1281-1286.
Gielen, S., de Backer, G., Piepoli, M.F., dan Wood, D. 2015. The ESC Textbook of Preventive Cardiology. Oxford University Press, UK.
Gunnell, A., Nedkoff, L., Hung, J., Knuiman, M., Gillies, M., Ortiz, M., et al. 2015. Cardioprotective drugs dispensed after admission for myocardial infarction (MI) in a whole population cohort: Western Australian Medication Adherence and Costs in Heart disease study (WAMACH). Heart, Lung and Circulation, 24, S377-S378.
Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342: 145–153.
Kishi, Y., Ohta, S., Kasuya, N., Sakita, S.Y., Ashikaga, T., dan Isobe, M. 2003, Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells, J Hypertens, 21:1347-1353.
Klingbeil, A.U., John, S., Schneider, M.P., Jacobi, J., Handrock, R., dan Schmieder, R.E. 2002, AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study, J Hypertens, 20:2423-2438.
Klingbeil, A.U., John, S., Schneider, M.P., Jacobi, J., Handrock, R., dan Schmieder, R.E. 2003, Effect of AT1 receptor blockade on endothelial function in essential hypertension, Am J Hypertens, 16:123-128.
Ko, D., Azizi, P., Koh, M., Chong, A., Austin, P., Stukel, T., & Jackevicius, C. 2019. Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction. Open heart, 6(1).
Law M.R., Wald N.J., Morris J.K., dan Jordan R.E. 2003, Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials, BMJ, 326:1427.
Loftus, I. M., Naylor, A. R., Goodall, S., Crowther, M., Jones, L., Bell, P. R., & Thompson, M. M. 2000. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke, 31(1), 40-47.
Lu, G. C., Cheng, J.W., Zhu, K.M., Ma, X.J., Shen, F.M., dan Su, D.F. 2009, A systematic review of angiotensin receptor blockers in preventing stroke, Stroke, 40:3876-3878.
Minai, K., Matsumoto, T., Horie, H., Ohira, N., Takashima, H., Yokohama, H., et al. 2001, Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors, J Am Coll Cardiol, 37:1565-1570.
Munger, M.A. 2011, Use of angiotensin receptor blockers in cardiovascular protection current evidence and future directions, Pharmacy and Therapeutics, 36: 22-40.
Nafrialdi. 2007, Antihipertensi, Gaya baru, Jakarta.
Neal, B., MacMahon, S., Chapman, N., Blood Pressure Lowering Treatment Trialists’ Collaboration. 2000, Effect of
ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials, Lancet, 355:1955–1964.
Omboni, S., Malacco, E., Mallion, J.M., Volpe, M., dan Zanchetti, A. 2012, Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, doubleblind, parallel-group studies, J Hypertens, 30:1468-1477.
Omboni, S dan Volpe, M. 2019, Angiotensin Receptor Blockers versus Angiotensin Converting Enzyme Ihibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan, Adv Ther, 36:278-297.
O’Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E. Jr., Chung, M.K., de Lemos, J.A., et al. 2013, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the ACCF/AMA Task Force on Practice Guidelines, Circulation, 127:362-425.
Pai, P.Y., Muo, C.H., Sung, F.C., Ho, H.C., dan Lee, Y.T. 2016, Angiotensin receptor blockers (ARB) outperform angiotensin converting enzyme (ACE) inhibitors on ischemic stroke precention in patients with hypertension and diabetes – A real world population in Taiwan, Int J Cardio, 215:114-119.
Perki. 2018, Pedoman Tata Laksana Sindrom Koroner Akut, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Jakarta.
Prasad, A., Halcox, J.P., Waclawiw, M.A., dan Quyyumi, A.A. 2001, Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis, J Am Coll Cardiol, 38:1089-1095.
Reboldi, G., Angeli, F., Cavallini, C., Gentile, G., Mancia, G., dan Verdecchia, P. 2008, Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis, J Hypertens, 26:1282–1289.
Schmieder, R. E. 2005. Mechanisms for the clinical benefits of angiotensin II receptor blockers. American journal of hypertension, 18(5), 720-730.
Simko, F., & Adamcova, M. 2018. What prevents cardioprotective drugs from reaching the market? Expert review of clinical pharmacology, 11(5), 463-465.
Smith, S.C., Jr, Allen J., Blair, S.N., Bonow, R.D., Brass, L.M., Fonarow, G.C., et al. 2006, AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute, Circulation, 113:2363–2372.
Stanek, E. J., Sarawate, C., Willey, V. J., Charland, S. L., & Cziraky, M. J. 2007. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Current medical research and opinion, 23(3), 553-563.
Strauss, M.H. dan Hall, A.S. 2006, Angiotensin receptor blockers may increase risk of myocardial infarction unraveling the ARB-MI paradox, Circulation, 114:838-854.
Strauss MH, Hall AS. 2017, Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB–MI paradox. Circulation, 135:2088–2090.
Taddei, S., & Bortolotto, L. 2016. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. American Journal of Cardiovascular Drugs, 16(5), 309-321.
Thomopoulos, C., Parati, G., dan Zanchetti, A. 2015, Effects of blood pressure lowering on outcome incidence in hypertension, 4: effects of various classes of antihypertensive drugs: overview and meta-analyses, J Hypertens, 33:195–211.
Tsuyuki, R.T. dan McDonald, M.A. 2006, Angiotensin receptor blockers do not increase risk of myocardial infarction, Circulation, 114:855-860.
Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. 2003, Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials, Lancet, 362:1527–1535.
Van Vark, L.C., Bertrand, M., Akkerhuis, K.M., Brugts, J.J., Fox, K., Mourand, J.J., et al. 2012, Angiotensin-converting enzyme inhibitos reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosteron system inhibitors involving 158998 patients, Eur Heart J, 33:2088-2097.
Velazquez, E. J., Pfeffer, M. A., McMurray, J. V., Maggioni, A. P., Rouleau, J. L., Van de Werf, F., ... & VALIANT Investigators, F. T. 2003. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure, 5(4), 537-544.
Weiss, D., Sorescu, D., dan Taylor, W.R. 2001, Angiotensin II and atherosclerosis. Am J Cardiol, 87:25C-32C.
Wu, L., Iwai, M., Nakagami, H., Li, Z., Chen, R., Suzuki, J., et al. 2001, Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury, Circulation, 104: 2716-2721.
Yang, J.H., Hahn, J.Y., Song, Y.B., Choi, S.H., Choi, J.H., Lee, S.H., et al. 2014, Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study, BMJ, 349.
Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., et al. 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358:1547-1559.
DOI: https://doi.org/10.24198/farmaka.v19i4.34939
DOI (PDF): https://doi.org/10.24198/farmaka.v19i4.34939.g16846
Refbacks
- Saat ini tidak ada refbacks.
Sitasi manajer:
Jurnal ini diindeks dalam:
Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Copyright © 2013 Jurnal Farmaka - All Right Reserved